| Prev Close | 6.16 |
| Open | 6.15 |
| Day Low/High | 6.03 / 6.20 |
| 52 Wk Low/High | 3.08 / 8.55 |
| Volume | 54.34K |
| Avg Volume | 238.60K |
| Exchange | NASDAQ |
| Shares Outstanding | 14.98M |
| Market Cap | 93.19M |
| EPS | -0.90 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Investors in Oncolytics Biotech Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCY options chain for the new May 17th contracts and identified the following call contract of particular interest.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Keep these health care stocks on your radar.
These under-$10 biotech stocks are within range of triggering breakout trades.
These under-$10 stocks look ready to trade higher from current levels.
Advanced Micro and Alaska Communications lead nine stocks trading under $5 as speculative stocking stuffers for possible positive returns in 2014.
Levi & Korsinsky is investigating Oncolytics Biotech Inc. (“Oncolytics” or the “Company”) (NasdaqCM: ONCY) for possible violations of federal securities laws.
There are too many red flags to count in the way Oncolytics Biotech spins results from the Reolysin head and neck cancer study.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Oncolytics claims positive Reolysin results, fails to mention falling response rates.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Crish Lau, Kapitall Contributor  Companies in the biotechnology space are often trade like speculative investments. Speculation for FDA approvals may [...]
The major U.S. equity averages edge up ahead of the central bank's policy decision on Thursday. Apple shares enjoy a boost from the debut of the iPhone 5.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
TheStreet's biotech columnist, Adam Feuerstein, will be providing live coverage from the BIO CEO biotech investor conference.
Amgen's purchases BioVex to get into the cancer immunotherapy game.
Speculative opportunities abound in the small- and mid-cap universe, but only for aggressive market players.
Every quarter brings a few surprises, and this one could be open to more heading into the November elections.
Several stocks trading near $5, including Columbia Laboratories, were poised to move on above-average volume Tuesday.
Several stocks trading under $5 were poised to move on above-average volume during Wednesday's session.
The Pantry tumbles on guidance.
GlaxoSmithKline falls on disappointing quarterly results.
Discovery Laboratories is rising.
Globalstar falls due to concerns over deterioration of its satellites.
Biogen and Elan lead the sector lower after Tysabri is pulled.
Focusing on terror threats, markets have been locked in an 8% range for 128 consecutive sessions.
